NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $5.90 +0.14 (+2.34%) As of 01:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cytek Biosciences Stock (NASDAQ:CTKB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytek Biosciences alerts:Sign Up Key Stats Today's Range$5.67▼$5.9050-Day Range$4.16▼$5.7652-Week Range$3.31▼$6.18Volume382,801 shsAverage Volume1.04 million shsMarket Capitalization$766.25 millionP/E RatioN/ADividend YieldN/APrice Target$5.56Consensus RatingHold Company Overview Cytek Biosciences, Inc. (NASDAQ: CTKB) develops and manufactures cell analysis solutions for research, clinical, and biopharmaceutical applications. The company is best known for its full-spectrum flow cytometry technology, which is designed to measure multiple cellular characteristics simultaneously and support the analysis of complex biological samples. Cytek’s product portfolio includes the Aurora and Northern Lights flow cytometers, which serve a range of laboratory needs from high-parameter research to more routine cell analysis. The company also offers reagents, including fluorochrome-conjugated antibodies, as well as software and related services intended to support instrument operation, data analysis, and laboratory workflows. Founded in 2014 and headquartered in Fremont, California, Cytek serves customers in the academic, pharmaceutical, biotechnology, clinical research, and government sectors. Its products are marketed internationally through direct sales and distribution channels. The company became publicly traded on the Nasdaq exchange in 2021.AI Generated. May Contain Errors. Read More Cytek Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreCTKB MarketRank™: Cytek Biosciences scored higher than 19% of companies evaluated by MarketBeat, and ranked 812th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingCytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Cytek Biosciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCytek Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.30) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -9.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytek Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.50% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 5.74.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentCytek Biosciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cytek Biosciences this week, compared to 3 articles on an average week.Search Interest1 people have searched for CTKB on MarketBeat in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.36% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTKB Stock News HeadlinesCytek Biosciences Tightens Shareholder Proposal Governance RulesSeptember 29 at 4:51 PM | tipranks.comFund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining ProfitabilitySeptember 29 at 11:51 AM | insidermonkey.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 30 at 1:00 AM | TradeSmith (Ad)Cytek Biosciences, Inc. Expands Cytek Cloud Digital Ecosystem With New Cloud Analysis ToolSeptember 24, 2026 | marketscreener.comMCytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis ToolSeptember 23, 2026 | globenewswire.comAnalysts Set Cytek Biosciences, Inc. (NASDAQ:CTKB) Price Target at $5.56September 23, 2026 | americanbankingnews.comCytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comCytek Biosciences, Inc. (CTKB)September 10, 2026 | finance.yahoo.comSee More Headlines CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $5.05 at the beginning of the year. Since then, CTKB stock has increased by 15.5% and is now trading at $5.8350. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.00. The company had revenue of $48.14 million for the quarter, compared to the consensus estimate of $47.31 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 12.40% and a negative net margin of 38.98%. Read the conference call transcript. How will Cytek Biosciences' stock buyback program work? Cytek Biosciences' board initiated a stock buyback plan on Monday, December 30th 2024, which allows the company to buy back $50,000,000 in shares, according to EventVestor. This means that the company could purchase up to 5.9% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its stock is undervalued. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Thursday, July 22nd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytek Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings8/05/2026Today9/30/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CTKB's financial health is in the Green zone, according to TradeSmith. CTKB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CTKB CIK1831915 Webwww.cytekbio.com Phone877-922-9835FaxN/AEmployees702Year Founded1992Price Target and Rating Average Price Target for Cytek Biosciences$5.56 High Price Target$7.50 Low Price Target$4.75 Potential Upside/Downside-4.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.54 million Net Margins-38.98% Pretax Margin-19.75% Return on Equity-12.40% Return on Assets-9.17% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio3.86 Sales & Book Value Annual Sales$206.71 million Price / Sales3.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.19Miscellaneous Outstanding Shares129,983,000Free Float116,517,000Market Cap$758.45 million OptionableOptionable Beta1.18 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CTKB) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC embeds molecular-level markers into plastics, metals, fuels, and textiles, giving e...Equiscreen | SponsoredLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTKB Stock Alerts